Literature DB >> 29198001

Imaging findings of recurrent pancreatic cancer following resection.

S Javadi1, N Karbasian2, P Bhosale3, S de Castro Faria3, O Le3, M H Katz4, E J Koay5, E P Tamm3.   

Abstract

Pancreatic cancer is a challenging malignancy to treat, largely due to aggressive regional involvement, early systemic dissemination, high recurrence rate, and subsequent low patient survival. Generally, 15-20% of newly diagnosed pancreatic cancers are candidates for possible curative resection. Eighty percent of these patients, however, will experience locoregional or distant recurrence in first 2 years. Although there is no strong evidence-based guideline for optimal surveillance after pancreatic cancer resection, careful comparison of surveillance follow-up multi-detector CT (MDCT) studies with a postoperative baseline MDCT examination aids detection of early recurrent pancreatic cancer. In this review article, we describe imaging findings suggestive of recurrent pancreatic cancer and review routine and alternative imaging options.

Entities:  

Keywords:  Dual-energy perfusion CT; MRI; Multi-detector CT; PET/CT; Recurrent pancreatic cancer

Mesh:

Year:  2018        PMID: 29198001     DOI: 10.1007/s00261-017-1397-8

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  6 in total

1.  Mediastinum metastasis in a post-surgical pancreatic cancer patient successfully confirmed with endoscopic ultrasonography.

Authors:  Hong-Tao Wei; Guang-Yong Chen; Peng Li
Journal:  World J Emerg Med       Date:  2021

2.  Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of abdominal radiology disease focus panel on PDAC.

Authors:  Linda C Chu; Zhen J Wang; Avinash Kambadakone; Elizabeth M Hecht; Jin He; Amol K Narang; Daniel A Laheru; Hina Arif-Tiwari; Priya Bhosale; Candice W Bolan; Olga R Brook; Abraham F Bezuidenhout; Richard K G Do; Samuel J Galgano; Ajit H Goenka; Alexander R Guimaraes; David M Hough; Naveen Kulkarni; Ott Le; Lyndon Luk; Lorenzo Mannelli; Michael Rosenthal; Guillermo Sangster; Zarine K Shah; Erik V Soloff; Parag P Tolat; Marc Zins; Elliot K Fishman; Eric P Tamm; Atif Zaheer
Journal:  Abdom Radiol (NY)       Date:  2022-10-14

3.  ISOlation Procedure vs. conventional procedure during Distal Pancreatectomy (ISOP-DP trial): study protocol for a randomized controlled trial.

Authors:  Ken-Ichi Okada; Manabu Kawai; Seiko Hirono; Masayuki Sho; Masaji Tani; Ippei Matsumoto; Suguru Yamada; Ryosuke Amano; Hirochika Toyama; Yo-Ichi Yamashita; Takeshi Gocho; Kazuto Shibuya; Minako Nagai; Hiromitsu Maehira; Keiko Kamei; Go Ohira; Yoshihiro Shirai; Hideki Takami; Nana Kimura; Takumi Fukumoto; Hideo Baba; Yasuhiro Kodera; Akimasa Nakao; Toshio Shimokawa; Masahiro Katsuda; Hiroki Yamaue
Journal:  Trials       Date:  2021-09-16       Impact factor: 2.279

4.  The Diagnostic Performance of 18F-FDG PET/CT in Recurrent Pancreatic Cancer: A Systematic Review and Meta-analysis.

Authors:  Gu A; Yuezhan Shan; Huasong Huo; Chao Ding; Caixia Sun
Journal:  Appl Bionics Biomech       Date:  2022-06-15       Impact factor: 1.664

5.  AMP‑activated protein kinase family member 5 is an independent prognostic indicator of pancreatic adenocarcinoma: A study based on The Cancer Genome Atlas.

Authors:  Haokai Xu; Jiayan Mao; Xiaodan Yang; Fei Chen; Zhengwei Song; Jianguo Fei; Wei Chen; Zhengxiang Zhong; Xiaoguang Wang
Journal:  Mol Med Rep       Date:  2020-09-10       Impact factor: 2.952

Review 6.  The clinical application of 18F-FDG PET/CT in pancreatic cancer: a narrative review.

Authors:  Yongzhu Pu; Chun Wang; Sheng Zhao; Ran Xie; Lei Zhao; Kun Li; Conghui Yang; Rui Zhang; Yadong Tian; Lixian Tan; Jindan Li; Shujuan Li; Long Chen; Hua Sun
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.